Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2017

01-02-2017 | Original Article

Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205

Authors: Hong-Yan Zhang, Feng Liang, Jian-Wei Zhang, Fei Wang, Li Wang, Xi-Gang Kang

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2017

Login to get access

Abstract

Purpose

To explore how long noncoding RNA-ROR (lncRNA-ROR) affects the tamoxifen resistance of breast cancer cells.

Methods

Breast epithelial (MCF10A), breast cancer (MCF7), and natural tamoxifen-resistant breast cancer (MDA-MB-231) cell lines were selected, and the relative lncRNA-ROR expressions were detected using quantitative real-time polymerase chain reaction (qRT-PCR). In vitro induction of TR5 cell line was performed. There were six groups: MCF7, MCF7/TR5, MDA-MB-231, MCF7-ROR, MCF7/TR5 ROR-siRNA, and the MDA-MB-231 ROR-siRNA groups. CCK-8 assay was conducted to assess the changes in drug resistance of each group. The expression of the epithelial mesenchymal transition (EMT) marker was detected using Western blotting. Transwell was selected to test the invasive ability of the cells. Expressions of microRNA-205 (miR-205) and ZEB1/2 were detected using qRT-PCR .

Results

Compared with the MCF7 cells, the proliferation rates of the MCF7/TR5 and MDA-MB-231 cells were significantly increased. Compared with the MCF7 cells, the MCF7-ROR cells had remarkably higher proliferation rates, down-regulated E-cadherin and miR-205 expressions, as well as increased vimentin, invasive ability, and mRNA expression of ZEB1 and ZEB2. Compared with the MCF7/TR5 and MDA-MB-231 cells, up-regulated E-cadherin and miR-205 expression, down-regulated expression of vimentin, ZEB1, and ZEB2 mRNA, and decreased invasive ability were observed in the MCF7/TR5 ROR-siRNA and MDA-MB-231 ROR-siRNA cells.

Conclusion

In MDA-MB-231 cells, down-regulated lncRNA-ROR could inhibit the EMT of breast cancer cells and enhance the sensibility of breast cancer cells to tamoxifen by increasing miR-205 expression and suppressing the expressions of ZEB1 and ZEB2.
Literature
1.
Igene H (2008) Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J 14:428–434CrossRefPubMed
2.
Travis RC, Reeves GK, Green J et al (2010) Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375:2143–2151CrossRefPubMedPubMedCentral
3.
Zheng S, Bai JQ, Li J et al (2012) The pathologic characteristics of breast cancer in China and its shift during 1999–2008: a national-wide multicenter cross-sectional image over 10 years. Int J Cancer 131:2622–2631CrossRefPubMed
4.
Jordan VC, O’Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25:5815–5824CrossRefPubMed
5.
Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247–263CrossRefPubMed
6.
Carroll JS, Brown M (2006) Estrogen receptor target gene: an evolving concept. Mol Endocrinol 20:1707–1714CrossRefPubMed
7.
Zafra-Ceres M, de Haro T, Farez-Vidal E et al (2013) Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer. Int J Med Sci 10:932–937CrossRefPubMedPubMedCentral
8.
9.
10.
Brunner AL, Beck AH, Edris B et al (2012) Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol 13:R75CrossRefPubMedPubMedCentral
11.
Zhang A, Zhou N, Huang J et al (2013) The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res 23:340–350CrossRefPubMed
12.
Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q (2015) lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res (MCR) 13:330–338CrossRef
13.
Feng S, Yao J, Chen Y et al (2015) Expression and functional role of reprogramming-related long noncoding RNA (lincRNA-ROR) in glioma. J Mol Neurosci (MN) 56:623–630CrossRef
14.
Kim J, Lee J, Jang SY, Kim C, Choi Y, Kim A (2016) Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. Oncol Rep 35:2553–2560PubMedPubMedCentral
15.
16.
Hiscox S, Jiang WG, Obermeier K et al (2006) Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118:290–301CrossRefPubMed
17.
Bremnes RM, Veve R, Hirsch FR, Franklin WA (2002) The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36:115–124CrossRefPubMed
18.
Schepens B, Tinton SA, Bruynooghe Y, Beyaert R, Cornelis S (2005) The polypyrimidine tract-binding protein stimulates HIF-1alpha IRES-mediated translation during hypoxia. Nucleic Acids Res 33:6884–6894CrossRefPubMedPubMedCentral
19.
Galban S, Kuwano Y, Pullmann R Jr et al (2008) RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol 28:93–107CrossRefPubMed
20.
21.
Gregory PA, Bert AG, Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601CrossRefPubMed
22.
Hurteau GJ, Spivack SD, Brock GJ (2006) Potential mRNA degradation targets of hsa-miR-200c, identified using informatics and qRT-PCR. Cell Cycle 5:1951–1956CrossRefPubMed
23.
Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH (2007) miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 13:1172–1178CrossRefPubMedPubMedCentral
24.
Hurteau GJ, Carlson JA, Spivack SD, Brock GJ (2007) Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 67:7972–7976CrossRefPubMed
25.
Sanchez-Tillo E, Siles L, de Barrios O et al (2011) Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res 1:897–912PubMedPubMedCentral
26.
Gheldof A, Hulpiau P, van Roy F, De Craene B, Berx G (2012) Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci (CMLS) 69:2527–2541CrossRef
27.
Vandewalle C, Van Roy F, Berx G (2009) The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci (CMLS) 66:773–787CrossRef
28.
Kato M, Zhang J, Wang M et al (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 104:3432–3437CrossRefPubMedPubMedCentral
29.
Baffa R, Fassan M, Volinia S et al (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219:214–221CrossRefPubMed
30.
31.
Kent OA, McCall MN, Cornish TC, Halushka MK (2014) Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucl Acids Res 42:7528–7538CrossRefPubMedPubMedCentral
Metadata
Title
Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205
Authors
Hong-Yan Zhang
Feng Liang
Jian-Wei Zhang
Fei Wang
Li Wang
Xi-Gang Kang
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3208-2

Other articles of this Issue 2/2017

Cancer Chemotherapy and Pharmacology 2/2017 Go to the issue

Original Article

Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways

Original Article

Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer

Original Article

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

Review Article

Clinical research on rare diseases of children: neuroblastoma

Original Article

Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate

Original Article

The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits